BNTX Earnings Prediction
The chart below shows how BNTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BNTX sees a +0.26% change in stock price 10 days leading up to the earnings, and a +1.35% change 10 days following the report. On the earnings day itself, the stock moves by -2.11%. This data can give you a slight idea of what to expect for the next quarter's release.
BNTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.24B
39.04%
867.21%
Gross Margin
88.82%
8.41%
18.46%
Operating Margin
3.23%
-64.70%
-100.46%
Net Margin
15.91%
-11.32%
-102.53%
EPS
0.81
20.90%
-124.11%
No Data Available
BNTX Earnings Analysis
BioNTech SE American Depositary Share Corporation (BNTX.O) Earnings Conference Call
Positive
Revenue Comparison Q3 2023: Total revenues reported for the period were approximately €1.245 billion, mostly recorded in September, compared to approximately €895 million for the third quarter of 2023.
COVID-19 Vaccine Approval Impact: The increase compared to the same period last year can be largely attributed to earlier approvals of our variant-adapted COVID-19 vaccines this year versus last year.
Cost of Sales Comparison: Cost of sales amounted to approximately €179 million for the third quarter of 2024 compared to approximately €162 million for the comparative prior-year period.
R&D Expense Increase: Research and development expenses were approximately €550 million for the third quarter of 2024 compared to approximately €498 million for the comparative prior-year period.
Net Income Increase: We reported a net income of approximately €198 million compared to about €161 million for the comparative prior-year period.
Negative
Revenue Comparison Q3 2023: The total revenues reported for the period were approximately €1.245 billion, mostly recorded in September, compared to approximately €895 million for the third quarter of 2023.
Cost of Sales Comparison: Cost of sales amounted to approximately €179 million for the third quarter of 2024 compared to approximately €162 million for the comparative prior-year period.
R&D Expense Increase: Research and development expenses were approximately €550 million for the third quarter of 2024 compared to approximately €498 million for the comparative prior-year period.
Operating Results Decline: The company's other operating results amounted to approximately negative €355 million in the third quarter of 2024 compared to negative €9 million for the comparative prior-year period.
Income Tax Comparison Q3: Income taxes were realized with an amount of about €39 million in the third quarter of 2024 compared to approximately €67 million of accrued tax expenses for the comparative prior-year period.
BNTX FAQs
How does BNTX typically perform around its earnings report dates?
Is BioNTech SE (BNTX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BNTX Earning Call Sentiment
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BNTX.O
-4.56%Positive
The earnings call summary shows strong financial performance with a 39% revenue increase and a 23% rise in net income, which is positive. However, the lack of specific shareholder return plans, significant accruals for contractual disputes, and guidance at the low end due to low demand in some regions temper the positivity. The Q&A session highlights some unclear responses regarding legal provisions, adding uncertainty. Overall, these mixed signals suggest a neutral sentiment, with no major catalysts to drive a strong price movement in either direction.
